Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
4 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease(Oxford University Press (OUP), 2024-08) ;Liabeuf, Sophie ;Hafez, Gaye ;Pešić, Vesna; Bobot, MickaëlThe relationship between chronic kidney disease (CKD) and cognitive function has received increased attention in recent years. Antibacterial agents (ABs) represent a critical component of therapy regimens in patients with CKD due to increased susceptibility to infections. Following our reviewing work on the neurocognitive impact of long-term medications in patients with CKD, we propose to focus on AB-induced direct and indirect consequences on cognitive function. Patients with CKD are predisposed to adverse drug reactions (ADRs) due to altered drug pharmacokinetics, glomerular filtration decline, and the potential disruption of the blood-brain barrier. ABs have been identified as a major cause of ADRs in vulnerable patient populations. This review examines the direct neurotoxic effects of AB classes (e.g. beta-lactams, fluoroquinolones, aminoglycosides, and metronidazole) on the central nervous system (CNS) in patients with CKD. We will mainly focus on the acute effects on the CNS associated with AB since they are the most extensively studied effects in CKD patients. Moreover, the review describes the modulation of the gut microbiota by ABs, potentially influencing CNS symptoms. The intricate brain-gut-kidney axis emerges as a pivotal focus, revealing the interplay between microbiota alterations induced by ABs and CNS manifestations in patients with CKD. The prevalence of antibiotic-associated encephalopathy in patients with CKD undergoing intravenous AB therapy supports the use of therapeutic drug monitoring for ABs to reduce the number and seriousness of ADRs in this patient population. In conclusion, elucidating AB-induced cognitive effects in patients with CKD demands a comprehensive understanding and tailored therapeutic strategies that account for altered pharmacokinetics and the brain-gut-kidney axis. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Case report: First diagnosis of Fabry disease in North Macedonia in a patient presenting with kidney failure on hemodialysis(Frontiers Media SA, 2024); ; ;Arsov, Todor; Fabry disease is a rare X-linked lysosomal storage disorder caused by α-galactosidase A (α-Gal A) deficiency. Reduced or absent enzyme activity causes progressive lysosomal accumulation of globotriaosylceramide (Lyso-Gb3) in various cells throughout the body to trigger inflammation and fibrosis. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Glomerulopathies with Fibrillary Deposits(Walter de Gruyter GmbH, 2023-07-01); ; ; ; The glomerulopathies associated with the deposition of extracellular fibrils in the glomeruli are subdivided into Congo red positive (amyloidosis) and Congo red negative (non-amyloidotic glomerulopathies) based on Congo red staining. The non-amyloidotic glomerulopathies are divided into immunoglobulin-derived and non-immunoglobulin-derived glomerulopathies. The immunoglobulin-derived glomerulopathies: fibrillary glomerulopathy (FGn) and immunotactoid glomerulopathy (ITG) are rare glomerulopathies. The diagnosis of fibrillary-immunotactoid glomerulopathy depends on electron microscopy, which shows the presence of microfibrils in the glomeruli. The microfibrils in FGn are randomly arranged with diameters less than 30 nm. The microfibrils in ITG are larger than 30 nm with a visible lumen (microtubules), focally arranged in parallel bundles. Patients with fibrillary-immunotactoid glomerulopathy present with proteinuria (usually in the nephrotic range), microscopic hematuria, arterial hypertension, and chronic kidney disease that progresses to kidney failure over months to years. Currently, there are no guidelines for the treatment of fibrillary-immunotactoid glomerulopathy, although immunotactoid glomerulopathy could be associated with underlying hematologic disorders with the need for clone-directed therapy. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, USE OF EVODIAL DIALIZERS FOR HEMODIALYSIS IN PATIENTS WITH HIGH RISK FOR BLEEDING - SINGLE CENTRE EXPERIENCE(Macedonian Association of Anatomists, 2023); ; ; ;SHpishikj Pushevska, AnamarijaMilenkova, MimozaDuring hemodialysis exposure of the blood to the dialysis membrane can promote clotting. So, usually anticoagulation is used. In patients with increased risk for bleeding heparin-free regime is mandatory. Evodial dialyzer contains a heparin-grafted membrane in order to reduce patients' bleeding risk. In this study we are showing our experience with the use of Evodial dialyzer. We report 106 dialysis sessions in 59 patients were performed. Reasons for using Evodial: active bleeding, hematological conditions, complications of vascular access. Changes in the dialyzer or additional interventions were examined. Low-dose unfractionated heparin was used in 10 (9,4%) sessions, and was added in 6 (5.7%) more and in another 5 ( 4,7%) saline flushing. In 4 (3,8%) sessions due to coagulation we had to terminate dialysis. Heparin-grafted dialyzers can be safely used in patients with high-risk for bleeding as reasonable alternative when regional citrate anticoagulation is unavailable.
